Nosis Launched Virtual Recovery Platform Nationwide

The company has expanded its substance use recovery program across all 50 states using a cash-pay business model.

Updated on Sept. 22, 2026 in Substance Abuse

Bold vector editorial illustration featuring a balance scale with fresh fruit and a plant, representing health and wellness. — Nosis has expanded its virtual recovery platform nationwide, utilizing a cash-pay model centered on metabolic health and personalized coaching to support substance use recovery. AI Illustration. Upload story photo >

Live Poll

Do you believe lifestyle and metabolic health support is essential for effective long-term recovery?

Nosis has officially launched its virtual recovery platform across the United States. The program focuses on the biological and metabolic needs associated with substance use disorder through personalized health coaching.

Why it matters

The platform aims to address underlying metabolic health factors that often coincide with substance use disorders. By focusing on nutrition, movement, and sleep, the program provides a holistic approach distinct from traditional clinical therapy.

The Nosis Blueprint assessment evaluates over 85 biomarkers to guide care, while the 12-week Nosis Core program is available for a launch price of $2,500. Ongoing monthly membership costs $299 after the initial assessment and foundational program.

The players

Nosis

A health company providing a virtual substance use recovery platform that focuses on biological and metabolic markers.

One Mind

A mental health research and advocacy organization that hosted a startup accelerator program earlier this year.

The details

Members interact with board-certified health coaches and registered dietitians via video and messaging to manage their recovery. The platform utilizes an AI-driven assessment to integrate health history and current symptoms into personalized interventions.

Nosis participated in a 10-week accelerator earlier in 2026.
The platform launched nationwide on September 22, 2026.
The company plans to introduce GLP-1 medications for cravings in early 2027.

The Big Picture

The launch follows Nosis's participation in the One Mind accelerator, marking its transition from a pilot phase to a national commercial offering. This move reflects a broader trend of virtual health startups targeting specialized recovery niches through direct-to-consumer models.

The platform offers an alternative for those seeking recovery support outside of traditional medication or therapy-based programs. Because it operates on a cash-pay model, users should consider the $2,500 core program investment against potential out-of-pocket costs for other recovery services.

The takeaway

Nosis offers a biological approach to recovery that emphasizes lifestyle interventions like nutrition and sleep. Potential users should be aware that the platform does not currently provide clinical therapy or medications for opioid use disorder.